Table 4 Data Inputs and distribution in Markov model
From: Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis
Variable | Mean/Mode | Distribution | Source |
|---|---|---|---|
Probabilities | Â | Â | Â |
Probabilities of non-symptomatic to stroke or CHD | See Table 2 | Gamma | 6 |
Probability from stroke to Death | 0.27 | Beta (α 0.27, β 0.73) | 29 |
Probability from CHD to Death | 0.51 | Beta (α 0.49, β 0.51) | 29 |
Relative Risk | Â | Â | Â |
Relative Risk of Thiazide to Stroke | 0.63 | Normal (α 0.63, se 0.056) | 4 |
Relative Risk of Thiazide to CHD | 0.84 | Normal (α 0.84, se 0.060) | 4 |
Relative Risk of Thiazide to Death | 0.89 | Normal (α 0.89, se 0.037) | 4 |
Relative Risk of Propranolol to Stroke | 0.83 | Normal (α 0.83, se 0.076) | 4 |
Relative Risk of Propranolol to CHD | 0.90 | Normal (α 0.90, se 0.071) | 4 |
Relative Risk of Propranolol to Death | 0.96 | Normal (α 0.96, se 0.056) | 4 |
Relative Risk of Lisinopril to Stroke | 0.65 | Normal (α 0.65, se 0.116) | 4 |
Relative Risk of Lisinopril to CHD | 0.81 | Normal (α 0.81, se 0.075) | 4 |
Relative Risk of Lisinopril to Death | 0.83 | Normal (α 0.83, se 0.071) | 4 |
Relative Risk of Nifedipine to Stroke | 0.58 | Normal (α 0.58, se 0.183) | 4 |
Relative Risk of Nifedipine to CHD | 0.77 | Normal (α 0.77, se 0.174) | 4 |
Relative Risk of Nifedipine to Death | 0.86 | Normal (α 0.86, se 0.120) | 4 |
Resources (Annual cost/patient in US Dollars) | Â | Â | Â |
Thiazide | 89.69 | Triangular (min 71.75, max 107.63) | 11 |
Propranolol | 103.36 | Triangular (min 82.69, max 124.03) | 11 |
Lisinopril | 404.08 | Triangular (min 323.26, max 484.89) | 11 |
Nifedipine | 294.72 | Triangular (min 235.78, max 353.67) | 11 |
Hospitalization cost for Stroke | 873.62 | Triangular (min 698.89, max 1048.34) | 11,12,UNTH |
Hospitalization cost for CHD | 311.73 | Triangular (min 249.39, max 374.08) | 11, UNTH |
Management of Stroke and CHD Patients | 417.74 | Triangular (min 334.20, max 501.29) | 11 |
Health Utilities | Â | Â | Â |
Hypertensive patients | 0.57 | Beta (α 206.1, β 155.1) | Unpublished |
Stroke Patients | 0.04 | Beta (α 1.0, β 23.3) | Unpublished |
CHD | 0.13 | Beta (α 4.9, β 32.9) | Unpublished |
Discount Rate | Â | Â | Â |
Cost and Utility | 3% | Triangular (min 0%, max 5%) | 30 |